KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

ACRETIN 0.025% CREAM

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

0.025%

 

GENERIC NAME:

TRETINOIN

 

MANUFACTURER:

JAMJOOM PHARMA

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Acne vulgaris

Hyperpigmentation, facial

Wrinkles, facial

 

SIDE EFFECTS:

Burning or stinging sensation of skin, severe

erythema, severe

hypopigmentation of treated skin

scaling of skin, severe

unusually dry skin, severe

Hyperpigmentation of treated skin

Burning sensation, stinging, or tingling of skin, mild

erythema, mild

scaling of skin, mild

unusually dry skin, mild

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Dermatitis, seborrheic

>> Eczema

Sensitivity to tretinoin

>> Sunburn

 

ADULT DOSE:

Hyperpigmentation, mottled, facial, due to photoaging (treatment adjunct) or Skin roughness, facial, due to photoaging (treatment adjunct) or Wrinkling, fine facial, due to photoaging (treatment adjunct) - Adults up to 50 years of age: Topical, to the skin of the face, a thin film once a day, usually at bedtime. Adults 50 years of age and older: Safety and efficacy have not been established. Note: Dosing is individualized to minimize irritation while maintaining efficacy. Alternate-day dosing, a smaller volume, or a weaker strength can be used initially or when skin becomes too irritated. If irritation becomes severe, tretinoin should be discontinued until irritation substantially lessens or heals. Safety and efficacy have not been established for daily use for more than forty-eight weeks. Some clinicians recommend only two or three applications per week following use for eight to twelve months to maintain effects.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Hyperpigmentation, mottled, facial, due to photoaging (treatment adjunct) or Skin roughness, facial, due to photoaging (treatment adjunct) or Wrinkling, fine facial, due to photoaging (treatment adjunct) - Adults 50 years of age and older: Safety and efficacy have not been established.

 

 

PREVIOUS

  

NEXT